Evry, France, December 19, 2007 – Novagali Pharma, an emerging ophthalmic pharmaceutical company announced that the Company’s Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic injectable emulsion based on EYEJECT® technology containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME), has been granted by the U.S. Food and Drug Administration (FDA)... Novagali's Press Release - Communiqué de Presse de Novagali-Tuesday, February 5, 2008
Novagali Pharma, FDA Clearance of IND for US Clinical Trial of Nova63035 in patients with Diabetic Macular Edema
Evry, France, December 19, 2007 – Novagali Pharma, an emerging ophthalmic pharmaceutical company announced that the Company’s Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic injectable emulsion based on EYEJECT® technology containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME), has been granted by the U.S. Food and Drug Administration (FDA)... Novagali's Press Release - Communiqué de Presse de Novagali-
